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Abstract
Introduction: Tamoxifen is one of the most effective adjuvant breast cancer therapies available. Its metabolism
involves the phase I enzyme, cytochrome P4502D6 (CYP2D6), encoded by the highly polymorphic CYP2D6 gene.
CYP2D6 variants resulting in poor metabolism of tamoxifen are hypothesised to reduce its efficacy. An FDA-
approved pre-treatment CYP2D6 gene testing assay is available. However, evidence from published studies
evaluating CYP2D6 variants as predictive factors of tamoxifen efficacy and clinical outcome are conflicting, querying
the clinical utility of CYP2D6 testing. We investigated the association of CYP2D6 variants with breast cancer specific
survival (BCSS) in breast cancer patients receiving tamoxifen.
Methods: This was a population based case-cohort study. We genotyped known functional variants (n = 7; minor
allele frequency (MAF) > 0.01) and single nucleotide polymorphisms (SNPs) (n = 5; MAF > 0.05) tagging all known
common variants (tagSNPs), in CYP2D6 in 6640 DNA samples from patients with invasive breast cancer from SEARCH
(Studies of Epidemiology and Risk factors in Cancer Heredity); 3155 cases had received tamoxifen therapy. There were
312 deaths from breast cancer, in the tamoxifen treated patients, with over 18000 years of cumulative follow-up. The
association between genotype and BCSS was evaluated using Cox proportional hazards regression analysis.
Results: In tamoxifen treated patients, there was weak evidence that the poor-metaboliser variant, CYP2D6*6 (MAF
= 0.01), was associated with decreased BCSS (P = 0.02; HR = 1.95; 95% CI = 1.12-3.40). No other variants, including
CYP2D6*4 (MAF = 0.20), previously reported to be associated with poorer clinical outcomes, were associated with
differences in BCSS, in either the tamoxifen or non-tamoxifen groups.
Conclusions: CYP2D6*6 may affect BCSS in tamoxifen-treated patients. However, the absence of an association
with survival in more frequent variants, including CYP2D6*4, questions the validity of the reported association
between CYP2D6 genotype and treatment response in breast cancer. Until larger, prospective studies confirming
any associations are available, routine CYP2D6 genetic testing should not be used in the clinical setting.
Introduction
Tamoxifen has been the standard treatment for oestro-
gen receptor (ER)-positive breast cancer for more than
three decades. Indications for its use [1] include:
metastatic disease in women (pre- and post-menopausal)
and men; adjuvant therapy in pre- and post-menopausal
women with breast cancer (lymph node positive and
negative); preventative therapy in women at high risk of
breast cancer; ductal carcinoma in situ post-resection;
and for the prevention of contra-lateral breast cancer.
There are proven benefits associated with five years of
tamoxifen treatment in ER-positive breast cancer
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recurrence rate, improved overall survival (OS) and a
reduction of the breast cancer mortality rate by a third
[2].
Tamoxifen is extensively metabolised after oral admin-
istration (Figure 1). N-desmethyl tamoxifen, the major
metabolite found in patients’ plasma, undergoes second-
ary metabolism to 4-hydroxy-N-desmethyl tamoxifen
(endoxifen). The enzyme involved in this conversion is
cytochrome P450 2D6 (CYP2D6), which also converts
tamoxifen to 4-hydroxy tamoxifen. This metabolite
undergoes secondary metabolism to endoxifen. It is
widely accepted that the majority of the anti-prolifera-
tive effect of tamoxifen occurs via its active metabolites
[3-5]. 4-hydroxy tamoxifen has at least 100-fold greater
affinity for the ER than tamoxifen, and has a similarly
increased potency in anti-proliferative action. Endoxifen
has an equivalent anti-proliferative potency and ER
binding ability to 4-hydroxy tamoxifen [6-8] but is pre-
sent in higher concentrations in the plasma.
Any factor that diminishes production of these meta-
bolites could impact on tamoxifen efficacy. Several
enzymes are involved in these metabolic pathways, with
CYP2D6 playing a pivotal role [9]. CYP2D6 is a poly-
morphic gene with over 90 documented alleles [10].
Some of these variants are associated with either
reduced or absent CYP2D6 enzyme activity. Pharmaco-
kinetic work using probe drugs such as debrisoquine
[11], first demonstrated the effects of CYP2D6 variants
on drug metaboliser status. CYP2D6 metaboliser func-
tion is generally categorised into four groups: poor-
metaboliser (PM); intermediate-metaboliser (IM); exten-
sive-metaboliser (EM) and ultra-metaboliser (UM) [12].
It has been hypothesised that patients with PM and IM
phenotypes generate reduced plasma concentrations of
active metabolites from a standard tamoxifen dose,
hence reducing its efficacy. Several studies have explored
the correlation between CYP2D6 genotype, and either
plasma metabolite levels and/or clinical outcome in
patients treated with tamoxifen. Ten studies have
demonstrated an association between putative PM var-
iants of CYP2D6 and poorer clinical outcome [13-22].
However other studies either found no such association
or the opposite results [23-26]. These studies have been
heterogeneous in both design and analytic methodology.
After reviewing five of these conflicting studies, Lash
and colleagues [27,28] concluded that the most straight-
forward explanation for the conflicting results is that the
null hypothesis cannot be rejected. The majority of
these studies use disease free survival (DFS) or progres-
sion free survival (PFS) as the clinical endpoints, but
there is considerable doubt about whether these are the
most valid endpoints, particularly in the adjuvant setting
where breast cancer specific survival (BCSS) or distant
d i s e a s ef r e es u r v i v a lm a yb ebetter endpoints [29]. Our
study primarily uses BCSS as the endpoint although OS
was also assessed.
The CYP2D locus contains three highly homologous
sequences of which CYP2D6 is the functional gene,
while CYP2D7 and CYP2D8 are non-functional pseudo-
genes [30,12]. CYP2D6 shares 93% sequence similarity
with CYP2D7 and 89% with CYP2D8 (BLAST
Figure 1 Tamoxifen metabolic pathway. CYP2D6, Cytochrome P450 2D6; CYP2D9, Cytochrome P450 2D9; CYP3A4, Cytochrome P450 3A4;
CYP3A5, Cytochrome P450 3A5; CYP2B6, Cytochrome P450 2B6; CYP2C19, Cytochrome P450 2C19.
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specificity of genotyping TaqMan assays for CYP2D6,
leading to unreliable genotype classifications and poten-
tially unreliable clinical associations. Hosking and collea-
gues [30] draw particular attention to this problem in
CYP2D6 in their article on detection of genotyping
errors by testing for deviation from Hardy-Weinberg
equilibrium (HWE P <0 . 0 5 )a n ds u c ht e s t i n gi sn o wa
well established part of genotyping quality control
[31,32]. Technical reasons such as assay non-specificity
can impact on the distribution of genotypes for any one
variant. When a variant deviates from HWE, the signifi-
cance of any association made is potentially unreliable.
Punglia and colleagues [33] performed a modelling
analysis to investigate whether women with EM geno-
types of CYP2D6 might have improved outcomes when
treated with tamoxifen rather than an aromatase inhibi-
tor (AI). They concluded that women carrying the EM
variants might have lower relapse rates when treated
with tamoxifen. Such modeling has limitations [34], but
if correct, CYP2D6 genotype would clearly influence the
decision to use either tamoxifen or AIs.
The Food and Drug Administration (FDA) approved
the diagnostic tool, the Amplichip® CYP450 Test, which
screens for 29 variants in the CYP2D6 gene and two in
CYP2C19 [35]. Prior to such a test being routinely
implemented in clinical practice, it is important that
large studies, with rigorous genotyping quality control
are used to assess the magnitude, if any, of the associa-
tion between CYP2D6 variants and valid clinical end-
points including BCSS and OS.C u r r e n t l y ,s u c hs t u d i e s
have not been published that establish the clinical utility
of CYP2D6 genotyping in determining treatment choice
or dose, in relation to tamoxifen therapy.
We have used two approaches to investigate the rela-
tion between germline variation in the CYP2D6 gene
and BCSS and OS in breast cancer patients treated with
tamoxifen. We evaluated the effect of single nucleotide
polymorphisms (SNPs) representing known functional
variants (PM, IM and UM; minor allele frequency
(MAF) > 0.01) on clinical outcome after adjuvant
tamoxifen therapy. We also carried out an empirical
evaluation of common genetic variation in CYP2D6 and
clinical outcome using a standard SNP tagging approach
that captures common variation without being depen-
dent on any prior knowledge of function.
Materials and methods
Study population
Breast cancer cases were drawn from Studies of Epide-
miology and Risk factors in Cancer Heredity (SEARCH),
an ongoing population-based case-control series, with
cases ascertained through the Eastern Cancer Registra-
tion and Information Centre (ECRIC) in England, a
regional population-based cancer registry. All women
diagnosed with invasive breast cancer before the age of
55 years since 1991 and still alive in 1996 (prevalent
cases, median age 48 years), together with all those diag-
n o s e db e f o r et h ea g eo f7 0y e a r sb e t w e e n1 9 9 6a n dt h e
present (incident cases, median age 54 years) were eligi-
ble to take part. All patients were non-metastatic at
recruitment. Questionnaires and a blood kit were sent
to eligible patients who had consented to participate.
The categories of information collected from the ques-
tionnaires included personal information, reproductive
history, medical history, drug/treatment history and
family history. Of those eligible, 67% returned question-
naires (6,951) and 64% (6,640) of those eligible provided
a blood sample for DNA analysis. Data on tumour mor-
phology, grade, and stage were obtained from the medi-
cal record. Eligible patients who did not take part were
similar to responders for age at diagnosis, histopatholo-
gical morphology and grade, but the proportion of clini-
cal stage III/IV cases was higher in non-participants.
The total number of cases available for analysis was
6,640; 5,349 (81%) incident cases and 1,291 (19%) preva-
lent cases. The study is approved by the Eastern Region
Multicentre Research Ethics Committee. All participants
provided written informed consent.
Information on the use of adjuvant hormone therapy
is obtained from the medical records by ECRIC, but
these data do not specify the drug used. We therefore
used the self-reported questionnaire data to identify
those women who had taken adjuvant tamoxifen.
Within the East Anglia/Cambridgeshire region tamoxi-
fen was the first-line adjuvant treatment until 2006,
except in the case of high risk, lymph node-positive
patients, where AIs have been in use since 2005. The
standard tamoxifen dose prescribed is 20 mg once daily.
Of the eligible cases, 3,155 confirmed treatment with
tamoxifen and 3,485 patients either did not receive any
adjuvant hormone therapy or they did not report what
type of hormone therapy they had taken. In order to
validate the questionnaire data, we checked the medical
records of 120 cases for treatment history and compared
this with questionnaire responses. The concordance rate
between self-reported treatment and treatment recorded
within the medical notes was 100%. Table 1 details the
characteristics of the study participants.
Concomitant medication
It has been postulated that concomitant use of drugs
that inhibit CYP2D6 function may also affect tamoxifen
efficacy and clinical outcome [7]. As part of the ques-
tionnaire, patients were requested to record current
medication at the time of recruitment. CYP2D6 inhibi-
tor (e.g. fluoxetine, cimetidine) use was recorded in 460
patients [see Supplementary table S1 in Additional file
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However, we cannot exclude use of such medication
pre-recruitment, and in addition we do not have details
of duration of treatment with CYP2D6 inhibitors.
Clinical follow-up
The ECRIC used active follow-up at three and five years
after diagnosis and then at five-year intervals until the
end of 2005. Follow-up information and OS (all-cause-
mortality) were obtained by searching hospital informa-
tion systems for recent visits. If a patient had not had a
recent visit, the patient’s general practitioner was con-
tacted to obtain the vital status. Continual, passive fol-
low-up is also carried out by death certificate flagging
through the Office of National Statistics. Since 2006, the
National Health Strategic Tracing Service has been
actively searched to determine the vital status of these
patients. The most recent search was on 31st July 2008.
The lag time with this process is a few weeks for cancer
deaths and two months to a year for non-cancer deaths
and so follow-up was censored six months before the
Table 1 Breast cancer patient characteristics
Patients WITH self-reported tamoxifen
treatment n = 3155
‡
†Patients WITHOUT self-reported tamoxifen
treatment n = 3485
‡
Median age 53 53
Age range 24-69 23-69
Tumour size group (cm) *N/A 913 (13.8%) 1,275 (19.2%)
<2 1,448 (21.8%) 1,380 (20.8%)
2-5 710 (10.7%) 751 (11.3%)
5+ 84 (1.3%) 79 (1.2%)
Grade 1 670 (10.1%) 599 (9%)
2 1,487 (22.4%) 1,318 (19.8%)
3 560 (8.4%) 1,019 (15.3%)
*N/A 438 (6.6%) 549 (8.3%)
Positive nodes 0 1,606 (24.2%) 1,476 (22.2%)
1-3 603 (9.1%) 591 (8.9%)
4-9 140 (2.1%) 200 (3%)
10+ 57 (0.9%) 78 (1.2%)
*N/A 749 (11.3%) 1,140 (17.2%)
Stage 1 1,624 (24.5%) 1,655 (24.9%)
2 1,359 (20.5%) 1,505 (22.7%)
3 99 (1.5%) 146 (2.2%)
4 28 (0.4%) 50 (0.8%)
*N/A 45 (0.7%) 129 (1.9%)
ER *N/A 959 (14.4%) 1,117 (16.8%)
(oestrogen receptor status) Negative 207 (3%) 668 (10.1%)
Positive 1,989 (30%)
§1,699 (25.6%)
Surgery Yes 1,982 (29.8%) 1,860 (28%)
No 132 (2%) 220 (3.3%)
*N/A 1,041 (15.7%) 1,405 (21.2%)
Chemotherapy Yes 587 (8.8%) 782 (11.8%)
No 1,527 (23%) 1,298 (19.5%)
*N/A 1,041 (15.7%) 1,405 (21.2%)
Person years follow-up 18,860.38 19,189.94
aNumber of events 312 418
*N/A - Data not available.
§Of 1,699 patients, 1,119 (16.9%) patients received hormone treatment but did not document which type; 3 (0.05%) had combined tamoxifen and aromatase
treatment; 232 (3.5%) received aromatase; 341(5.1%) received no hormone treatment; 4 (0.06%) patients had no data available.
†Some patients in this group stated that they received adjuvant hormone treatment but did not document which drug.
‡Percentages given are from total of 6,640.
aBreast cancer specific deaths.
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defined as a death in which breast cancer was given as
the cause of death on Part I of the death certificate. All-
cause mortality was defined as death from any cause.
Selection of functional SNPs and haplotypes
Many rare variants of CYP2D6 have been reported and
their nomenclature is complex [36]. Some of these var-
iants are single nucleotide changes and others are haplo-
types - alleles at multiple loci that are inherited
together. An extensive review of the literature identified
15 putative functional variants [37-42] that occur in
populations of European origin, of which seven of these
were successfully genotyped [see Supplementary table
S2 in Additional file 1]: CYP2D6*1; CYP2D6*4;
CYP2D6*5; CYP2D6*6b/c; CYP2D6*9; CYP2D6*10;
CYP2D6*41; CYP2D6*UM (UM refers to ultra-metaboli-
ser phenotype).
The CYP2D6*6 allele is defined by a frame-shift muta-
tion protein truncating deletion -1707delt.H o w e v e r ,w e
were unable to design a Taqman assay for this variant
and could not genotype it directly. This allele is sub-
divided into four sub-types: CYP2D6*6a; CYP2D6*6b;
CYP2D6*6c;a n dCYP2D6*6d. CYP2D6*6b and
CYP2D6*6c carry the 1976g>a variant, which we suc-
cessfully genotyped. There is little data in the literature
to determine the proportion of all CYP2D6*6 alleles that
are accounted for by CYP2D6*6b and CYP2D6*6c, but
any misclassification of CYP2D6*6 will be very small as
all the alleles are rare.
The association between individual PM variants
(CYP2D6*4; CYP2D6*5; CYP2D6*6)a n dB C S Sa n dO S
was assessed. Similarly, the association between indivi-
dual IM variants (CYP2D6*41; CYP2D6*9; CYP2D6*10)
and BCSS and OS were assessed. In addition, two PM/
IM combined models were also assessed for any associa-
tion with BCSS and OS. The unadjusted and adjusted
results, as well as the variables adjusted for are given in
Table 2. The PM/IM group are classified as carriers of
two variants (i.e. rare homozygote alleles) for at least
one of the SNPs associated with PM or IM variants as
stated previously. The PM/IM model 1 compares the
PM/IM group with individuals who carried two copies
of the wild-type (EM) allele at all SNPs (i.e. common
homozygotes) or individuals who carried a single variant
allele at a single SNP (i.e. heterozygotes). PM/IM model
2 compares individuals who carried two copies of the
w i l d - t y p ea l l e l e( E M )a ta l lS N P s( i . e .c o m m o n
homozygotes).
Selection of tag SNPs
SNP tagging aims to identify a set of SNPs (tagSNPs;
MAF > 0.05) that efficiently tags all the common varia-
tions in CYP2D6 with an estimated r
2 of more than 0.8.
R
2 is the square of the correlation coefficient between a
pair of SNPs. The loss in power incurred by using a
marker SNP in place of a true causal SNP is directly
related to r
2 v a l u ea se f f e c t i v es a m p l es i z ei sd i r e c t l y
proportional to r
2. Where the common variation has
not been systematically identified, a set of SNPs that
tags the known common variation will also tag any
hitherto unidentified SNPs in the gene with reasonable
efficiency [43]. Data from the International HapMap
Project [44] Europea ns a m p l e so f3 0p a r e n t - o f f s p r i n g
trios were used to select tagSNPs. The 4.4 kb CYP2D6
gene is not well represented in any SNP databases so to
obtain comprehensive coverage of the gene, a 100 kbp
region surrounding the CYP2D6 gene was included. Five
tagSNPs were selected using the aggressive 2- and 3-
SNP tagging option in the Tagger programme imple-
mented in Haploview. These five tagSNPs tagged 46 of
the 47 common SNPs (98%) with r
2 of more than 0.8.
Taqman genotyping
Genotyping was carried out using Taqman® (Applied
Biosystems Europe BV, UK Branch, Warrington, Che-
shire, UK) according to manufacturer’s instructions. Pri-
mers and FAM and VIC labelled probes were supplied
directly by Applied Biosystems (UK Branch, Warrington,
Cheshire, UK) as Assays-by-Design™.A l la s s a y sw e r e
carried out in 384-well plates. Each plate included nega-
tive controls (with no DNA) and 12 randomly dispersed
samples were selected from each 384-well plate and
duplicated on a separate concordance plate. The original
s a m p l ea n di t sd u p l i c a t ew e r et h e nc o m p a r e dt oe n s u r e
concordant genotype calls. Plates were read on the ABI
Prism 7900 using the Sequence Detection Software
(Applied Biosystems, UK Branch, Warrington, Cheshire,
UK). Failed genotypes were not repeated. Assays in
which the genotypes of duplicate samples did not show
more than 95% concordance were discarded and
replaced with alternative assays with the same tagging
properties. Call rates for each assay were above 95%.
Nested PCR genotyping
Initial attempts to genotype CYP2D6*4, with a specifi-
cally designed TaqMan assay and genomic DNA
resulted in poor segregation of genotypes on cluster
plots with overlapping clusters and errors in genotype
calls. The distribution of genotypes deviated significantly
from those expected under HWE. Direct sequencing of
selected DNA samples confirmed those errors in Taq-
Man genotyping calls. These errors are likely to be due
to the presence of the pseudogenes.
To increase assay specificity, we used a nested PCR
approach for CYP2D6*4 to pre-amplify CYP2D6-specific
template DNA prior to a standard TaqMan assay. We
designed a pair of primers flanking SNP CYP2D6*4 on
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the CYP2D6 gene (CYPD6 -F o r w a r dp r i m e r( F 1 ) :
5’GCATAGGGTTGGAGTGGGT3’; Reverse primer
(R3): 5’TCCTCGGTCTCTCGCTCCG3’ [see Supple-
mentary figure S1, sequence alignment, in Additional
file 2]. All genomic DNA samples were amplified using
this primer pair under the following PCR conditions: 1
× AmpliTaq Gold® Buffer II (ABI, Applied Biosystems
Europe BV, UK Branch, Warrington, Cheshire, UK),
2 mM MgCl2, 0.05 U/ul AmpliTaq Gold DNA Polymer-
ase (ABI, Applied Biosystems Europe BV, UK Branch,
Warrington, Cheshire, UK), 0.25 mM dNTPs mix, 0.5
uM of each primer, 1 ng/ul genomic DNA. PCR pro-
gram: 1) 95°C for 10 minutes; 2) 40 cycles of 94°C for
30 seconds, 66°C for 30 seconds, 72°C for 45 seconds; 3)
72°C for 10 minutes; 4) storage at 4°C. Aliquots of
Table 2 Results of unadjusted and adjusted Cox regression analysis for breast cancer specific survival in common
(tagSNPs) and functional polymorphisms of CYP2D6
No tamoxifen
(unadjusted)
All tamoxifen-treated
patients (unadjusted)
ER-positive patients
treated with tamoxifen
(unadjusted)
ER-positive patients
treated with tamoxifen
(adjusted)
†SNP Metaboliser
Status
MAF** P-
value
Hazard
ratio
95%
CI**
P-
value
Hazard
ratio
95%
CI**
P-
value
Hazard
ratio
95%
CI**
P-
value
Hazard
ratio
95%
CI**
CYP2D6 functional SNPs
CYP2D6*41 (IM) 0.09 0.89 1.02 0.72-
1.46
0.12 0.79 0.59-
1.07
0.43 0.85 0.57-
1.27
0.69 0.88 0.48-
1.62
CYP2D6*4 (PM) 0.2 0.34 0.88 0.69-
1.15
0.89 1.01 0.83-
1.24
0.93 1.01 0.78-
1.32
0.39 1.17 0.82-
1.68
CYP2D6*5 (PM) 0.04 0.49 2.01 0.28-
14.3
†n/a
†n/a
†n/a
†n/a
†n/a
†n/a
†n/a
†n/a
†n/a
‡CYP2D6*6 (PM) 0.01 0.76 1.17 0.43-
3.14
0.02 1.95 1.12-
3.40
0.04 2.14 1.05-
4.36
0.33 1.8 0.56-
5.80
CYP2D6*9 (IM) 0.03 0.53 0.8 0.40-
1.60
0.45 1.18 0.76-
1.83
0.62 1.18 0.62-
2.23
0.33 1.52 0.65-
3.52
CYP2D6*10 (IM) 0.02 0.93 0.96 0.42-
2.19
0.61 1.22 0.57-
2.59
†n/a
†n/a
†n/a
†n/a
†n/a
†n/a
CYP2D6*UM (UM) 0.08 0.65 1.57 0.22-
11.3
0.45 0.47 0.07-
3.34
†n/a
†n/a
†n/a
†n/a
†n/a
†n/a
§CYP2D6*PM
Model 1
(PM)
‡‡N/A 0.46 0.77 0.39-
1.52
0.78 0.93 0.55-
1.57
0.98 1.01 0.51-
2.00
0.32 1.57 0.64-
3.84
§§CYP2D6*PM
Model 2
(PM)
‡‡N/A 0.85 0.97 0.72-
1.31
0.63 1.06 0.84-
1.34
0.82 0.96 0.70-
1.32
0.21 1.35 0.84-
2.16
TagSNPs
CYP2D6_01t ¹N/A 0.32 0.33 0.89 0.71-
1.12
0.3 0.91 0.77-
1.08
0.97 1 0.79-
1.25
0.65 0.93 0.66-
1.3
CYP2D6_02t ¹N/A 0.46 0.07 1.21 0.98-
1.49
0.98 1 0.86-
1.17
0.89 0.98 0.79-
1.22
0.43 0.88 0.65-
1.20
CYP2D6_03t ¹N/A 0.24 0.18 0.84 0.65-
1.08
0.93 1.01 0.84-
1.21
0.93 1.01 0.79-
1.30
0.93 1.02 0.72-
1.43
CYP2D6_04t ¹N/A 0.08 0.34 1.19 0.83-
1.72
0.34 0.86 0.63-
1.17
0.88 1.03 0.70-
1.52
0.43 1.25 0.72-
2.19
CYP2D6_05t ¹N/A 0.22 0.41 0.9 0.69-
1.16
0.94 1.01 0.83-
1.22
0.48 0.91 0.69-
1.18
0.6 1.1 0.77-
1.59
*Adjusted values in all cases, except PM models, include adjustment for grade, stage, chemotherapy, surgery, lymph node status, ER and tumour size.
** 95% CI, 95% confidence interval; ER, oestrogen receptor; MAF, mean allele frequency; SNP, single nucleotide polymorphisms.
†n/a, No calculations possible due to low sample number.
§The PM group are classified as carriers of two variant alleles (rare homozygote alleles) for at least one of the functional SNPs associated with PM or intermediate
metaboliser (IM) status. Where IM = CYP2D6*41; CYP2D6*9; CYP2D6*10 and PM = CYP2D6*4; CYP2D6*5; CYP2D6*6. In CYP2D6*Poor Metaboliser (PM) Model 1:
the PM group (classified as stated) is compared with individuals who carried two copies of the wild-type allele (EM) at all SNPs (i.e. common homozygotes) or
individuals who carried a single variant allele at a single SNP (heterozygotes). Adjusted values in all cases include adjustment for grade, stage, chemotherapy,
surgery, tumour size and ER status.
§§The PM group was classified as individuals carrying at least one variant allele at one or more of the functional SNPs (heterozygotes and rare homozygotes),
associated with PM or intermediate metaboliser (IM) status. Where IM = CYP2D6*41; CYP2D6*9; CYP2D6*10 and PM = CYP2D6*4; CYP2D6*5; CYP2D6*6. In
CYP2D6*Poor Metaboliser (PM) Model 2: the PM group (classified as stated) is compared with individuals who carried two copies of the wild-type allele (EM) at
all SNPs (common homozygotes). Adjusted values in all cases include adjustment for grade, stage, chemotherapy, surgery, tumour size and ER status.
‡‡ N/A, not applicable.
‡CYP2D6*6 refers to the 1976g > a variant, which is associated with CYP2D6*6b and CYP2D6*6c.
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for genotyping with CYP2D6*4 TaqMan Assay. Geno-
types obtained were confirmed by direct sequencing of
selected samples.
Real-time PCR
The CYP2D6*5 (gene deletion) and CYP2D6*UM (gene
duplication) variants were identified using a biplex Taq-
man real-time quantification assay as per the Schaeffeler
and colleagues protocol [45]. Samples from patients
with the known genotype CY2D6*1/*1 (EM or wild-type
variant) were used to create the standard curve for the
real-time PCR analysis. Also analysed on the same plate
were samples with the known genotypes CY2D6*1/*5;
CY2D6*5/*5; CY2D6*1/*2×*1.N ok n o w nh o m o z y g o t e
CYP2D6*UM (CY2D6*2×*1/*2×*1) sample was available.
The samples with a homozygote deletion CY2D6*5/*5
were clearly identifiable; however, the range of expres-
sion values for CY2D6*1/*1, CY2D6*1/*5 and CY2D6*1/
*2×*1 did not make it possible to distinguish between
heterozygotes and common homozygotes. Homozygote
CYP2D6*UM were recognised as lying more than two
standard deviations from the wild-type and heterozygote
clusters.
Statistical methods
Cox regression analysis was used to test for an associa-
tion between SNP genotype, BCSS and OS (all-cause
mortality). The time at risk began on the date of diagno-
sis and time under observation began on the date of
blood sample receipt and ended on the date of death
from any cause, or, if death did not occur, on 31st Janu-
ary 2008. Thus, cases do not contribute to hazard esti-
mation until they are under observation. This allows for
the difference in ascertainment of incident and prevalent
cases. Proportional hazards is a property of the true
underlying biological model and not related to study
design. A recent publication by Azzato and colleagues
has demonstrated that the use of prevalent cases does
not result in a bias of the hazard ratio estimate, pro-
vided the proportional hazards assumption is correct
and the ‘left truncation’ (ascertainment/recruitment after
diagnosis) is properly accounted for in the analysis [46].
Follow-up was censored at 10 years after diagnosis,
because follow-up became less reliable for each indivi-
dual after 10 years. The proportional hazards assump-
tion was evaluated by visual inspection of log-log plots,
as well as tested analytically using Schoenfeld residuals.
We used a 1 degree of freedom (d.f.) trend test based
on the number of rare alleles carried as the primary test
of association, as the true underlying genetic model is
not known. This test provides reasonable power for
dominant or co-dominant genetic models, but limited
power if the underlying model is recessive. For the rare,
functional alleles, power to detect a recessive effect
would be extremely limited as individuals who carry two
copies of the minor allele are rare in the population.
Supplementary table S3 in Additional file 1 shows the
potential power of this study to detect a hazard ratio
(HR) of 1.85. The HR per number of rare alleles carried,
with associated 95% confidence limits, was estimated
from the Cox regression. All analyses were performed in
Intercooled Stata, version 10 (StataCorp LP, Texas,
USA).
Results
The five tagSNPs (MAF > 0.05) and seven putative func-
tional SNPs (MAF > 0.01) were genotyped in 6,640 cases
of predominantly Caucasian ethnicity (98.8%) [see Sup-
plementary table S2 in Additional file 1]. Greater than
97% of samples were successfully genotyped for each
SNP and the genotype distributions are shown in Sup-
plementary table S4 in Additional file 1. The results of
the association between each SNP and BCSS, according
to tamoxifen treatment status are shown in Table 2.
The results of the association between each SNP and
OS are shown in Supplementary table S5 in Additional
file 1. A summary of the results, independent of tamoxi-
fen status, are given in Supplementary table S6 in Addi-
tional file 1. We have adhered to the REMARK [47]
recommendations for reporting tumour marker studies
as these criteria create a coherent and transparent fra-
mework for the reporting a wider range of study designs
[see Supplementary table S7 in Additional file 3].
There was no statistically significant association
between BCSS or OS and genotype for any of the
tagSNPs for common variation at the CYP2D6 locus
either in patients receiving or not receiving tamoxifen.
There was no significant association between BCSS or
OS and the putative functional alleles termed CYP2D6-
*1; *4; *5; *9; *10; *41; *UM.O fp a r t i c u l a rn o t ei st h e
lack of association for the PM allele that has most com-
monly been reported to be associated with poorer clini-
cal outcome in a Caucasian population - CYP2D6*4 (For
BCSS: HR = 1.01; 95% confidence interval (CI) = 0.83 to
1.24; P = 0.89; and OS: HR = 1.06; 95% CI = 0.90 to
1.26; P = 0.5).
As patients may carry more than one variant allele
and the power to detect any single variant is limited, we
also classified individuals with at least one known func-
tional allele as PM/IM and individuals with two normal
alleles as EM. There was no difference in survival
between these two groups (BCSS: HR = 0.93; 95% CI =
0.55 to 1.57; P = 0.78 and OS: HR = 0.98; 95% CI =
0.63 to 1.54; P = 0.94). Nor was there a difference
between patients, carrying at least two variant alleles
compared with EM patients or those who carried just a
single variant (BCSS: HR = 1.06; 95% CI = 0.84 to 1.34;
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0.49). Individuals who were heterozygous at more than
one site were excluded as the haplotype arrangements of
these variants (whether they were arranged in cis or in
trans) could not be unequivocally determined.
We did find some evidence for association of one PM
variant, CYP2D6*6b/6c, with reduced BCSS and OS in
women treated with tamoxifen. Carriers of the minor
allele had poorer survival (BCSS: HR = 1.95; 95% CI =
1.12 to 3.40; P = 0.02 and OS: HR = 1.91; 95% CI =
1.18 to 3.11; P = 0.01). As expected for such a rare var-
iant (MAF = 0.01), no patients in this study were homo-
zygous for the minor allele. This association with
decreased BCSS becomes non-significant when
restricted to ER-positive patients who received tamoxi-
fen and after adjustment for the known prognostic fac-
tors: stage, grade, tumour size, nodal status, surgery, and
chemotherapy (Table 2; HR = 1.80; 95% CI = 0.56 to
5.80; P = 0.33). None of the other functional or tagSNPs
were associated with BCSS after adjustment for ER.
Homozygote deletions CY2D6*5/*5, and a combined
heterozygotes (CY2D6*1/*5 and CY2D6*1/*2×*1) and
common allele homozygotes (CY2D6*1/*1) group were
defined. Using our criteria, there were 40 CYP2D6*UM
in our study population, giving a MAF of 0.08. This is
higher than the previous reports of homozygote
CYP2D6*UM with a MAF of 0.02. During the analysis,
the association of CYP2D6*UM with BCSS was assessed
for CYP2D6*UM with a MAF of 0.08 and also
CYP2D6*UM with a MAF of 0.02 (previously reported
MAF). There was no significant association with either
BCSS or OS in either case.
Regardless of genotype, the use of CYP2D6 inhibitors
(e.g. fluoxetine, cimetidine) did not affect BCSS or OS
for patients either receiving tamoxifen treatment or not
receiving tamoxifen treatment. This was true for all
functional SNPs and tagSNPs.
Some of the studies reporting an association between
CYP2D6 PM variants and endpoints such as DFS or
time to relapse (TTR), had restricted their analysis to
post-menopausal women, who were ER positive but had
not received chemotherapy and who were treated with
tamoxifen. Unadjusted sub-group analysis of cases
restricted to these criteria in our study showed no asso-
ciation with BCSS or OS for either individual variants or
for combined PM/IM groups. Similarly, analysis of pre-
menopausal cases also showed no association with BCSS
or OS for either individual variants or for combined
PM/IM groups.
Genotyping this region of the genome is complicated
by the presence of pseudogenes. There is one variant for
which the genotype deviated significantly from HWE
CYP2D6*41 (PHWE =5 . 9 2×1 0
-6). Large deviations in
HWE may be indicative of poor genotyping specificity
as a result of cross-hybridisation of the assay with pseu-
dogene sequences. Potential misclassification of alleles
means that reported associations with these variants
should be treated with caution.
Discussion
This large study has investigated the association between
germ-line variation in CYP2D6 variants and BCSS in
3,155 patients treated with tamoxifen and 3,485 patients
who did not receive tamoxifen. The main strengths of
the study are the sample size, the comprehensive evalua-
tion of CYP2D6 variation, the systematic follow-up and
the high quality of genotyping assays using DNA
extracted from blood samples.
Our results suggest that just one putative PM variant,
CYP2D6*6 (1976g>a variant), may be associated with
decreased BCSS. This association cannot be considered
definitive because it is not highly statistically significant.
Wacholder and colleagues [48] define the false positive
reporting probability, which provides a useful framework
to evaluate the importance of any statistical association
that is dependent on the prior probability of association
and the power to detect that association. Although there
is good pharmacokinetic evidence to support the exis-
tence of PM and IM CYP2D6 variants, the evidence
linking these variants to clinical outcome in tamoxifen-
treated breast cancer patients is much weaker. Assuming
a prior probability of association of 1 in 10 for a hazard
ratio of 1.5 the association between CYP2D6*6 and out-
come has a 50% chance of being a false positive. For a
prior probability of 1 in 100, the false positive probabil-
ity is over 90%. No other tagSNPs or functional SNPs
showed any association with BCSS. Similarly, when con-
sidering the combinations of PM/IM variants the results
do not support the hypothesis that putative PM or IM
variants, in general are associated with poorer survival.
Our data support the conclusion of Lash and colleagues
[27,28] that CYP2D6 variants are not significantly asso-
ciated with outcome in women with breast cancer trea-
ted with adjuvant tamoxifen.
Supplementary table S8 in Additional file 1 sum-
marises the recent key studies, their results and meth-
ods. These studies are highly heterogeneous both in
methodology and results. Previous studies have reported
hazard ratios of over two for relapse free survival for dif-
ferent genotypes. Assuming a slightly weaker association
with BCSS (for example, HR = 1.85), we have 65%
power to detect a difference in a sub-group (defined by
genotype) of 1% of the patient population and over 90%
power to detect that difference in a subgroup of 2% of
the population [see Supplementary table S3 in Addi-
tional file 1]. The PM/IM1 group comprises 8.95% of
patients. We have over 90% power to detect a HR of
1.85 in this group. Thus, our study is extremely well
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reported. It is possible that one or more of these var-
iants are associated with a specific sub-group of cases,
but the number of ways of classifying tumours is large
and such a specific sub-group effect can rarely be
excluded. Furthermore, there are no published data sug-
gesting that an association would be limited to a more
specific sub-group of cases.
We detected a higher frequency of CYP2D6*UM in
this study than has been previously reported. This may
be the true value for our population, however, because
we had no homozygote CYP2D6*UM (CY2D6*2 × *1/*2
×* 1 )positive control, it is also possible that there has
been some misclassification.S o m eo ft h eh e t e r o z y g o t e
CYP2D6*UM may have been included in the homozy-
gote CYP2D6*UM group. However, to assess the poten-
tial effect of this on association with BCSS and OS, the
analysis was performed for CYP2D6*UM MAF of 0.08
and also CYP2D6*UM MAF of 0.02 (previously reported
MAF). Patients with the UM variant, which is predicted
to generate increased plasma concentrations of activate
metabolites, did not show any evidence of improved
BCSS or OS relative to EM, irrespective of whether the
MAF was 0.08 or 0.02.
The presence of the two highly homologous pseudo-
genes complicates the genotyping of CYP2D6 gene var-
iants [30,12]. For the CYP2D6*4 variant, a nested or
long range PCR approach is needed to ensure specificity
during genotyping. We used a nested PCR approach and
assessed the specificity of the primers by sequencing.
The use of inadequately specific primers may in some
variants lead to unreliable genotyping classification and
subsequent clinical associations. HWE may be used as
an aid to assess genotyping quality [31]. Examination of
published data shows that in some studies, the genotype
distribution of certain variants deviate significantly from
HWE, for example, Goetz and colleagues [13]
(CYP2D6*4 PHWE =2 . 4×1 0
-4) and Schroth and collea-
gues [21] (CYP2D6*4 PHWE = 0.009 and CYP2D6*10
PHWE =1 . 7×1 0
-7), suggesting that genotype classifica-
tion of this region of the genome is problematic, mean-
ing that any clinical associations found should be
interpreted with care. Such deviation from HWE is unli-
kely to be due simply to population admixture or the
fact that it is a patient cohort.
There may be some concern that the use of prevalent
cases is problematic in any time-to-event analysis even
though this was taken into account in the analysis. The
analysis was, therefore, repeated on the subset of the
subjects ascertained as incident cases. There was no
substantial difference in the HR estimates for
CYP2D6*6. The results showed CYP2D6*6 P =0 . 0 3 ,H R
=2 . 0 9a n d9 5 %C I=1 . 0 7t o4 . 0 7f o rt h ei n c i d e n tc a s e s
only analysis, in comparison to P = 0.02, HR = 1.95 and
95% CI = 1.12 to 3.40 when the analysis was completed
using both incident and prevalent cases combined. The
results for CYP2D6*4 for the incident cases again
showed no significant association with BCSS (P =0 . 4 ,
HR = 0.90, 95% CI = 0.70 to 1.15).
We have examined all the available evidence on
CYP2D6 variants and outcome for breast cancer patients
treated with adjuvant tamoxifen including our own data
presented here. Many studies have used PFS, DFS, or
TTR as the clinical endpoint of choice. It may be argued
that the effects of CYP2D6 genotypes are specific to
relapse and not death. However, DFS and PFS data are
not available for the patients in our study. Nevertheless,
it is very unlikely that any of these variants have a large
effect on BCSS with over seven years median follow-up
on patients treated with tamoxifen. Furthermore, it
could be argued that a difference in PFS is not clinically
useful if that does not result in an improvement in
BCSS [49].
Other potential weaknesses of our study also need to
be considered. Detailed information on patient compli-
ance and length of tamoxifen therapy are currently una-
vailable. However, given that the HR for CYP2D6*4 was
very close to unity (HR = 1.01), any true effect limited
to compliers would have had to have been balanced by
the opposite effect of greater magnitude in non-com-
pliers, which seems unlikely. Our evaluation of func-
tional variants was not comprehensive. We were not
able to assess CYP2D6*3 due to failure of manufacture
of an adequate Taqman assay. This would have resulted
in some misclassification of PM patients as EM, but this
misclassification will have been very small as CYP2D6*3
is found in 1 to 4% of the Caucasian population [50].
Furthermore, only 3 of the 12 published studies shown
in Supplementary table S8 in Additional file 1 investi-
gated this variant and none of these studies reported a
significant association for this variant individually.
O u rc a s es e r i e si su n s e l e c t e df o rf a m i l yh i s t o r ya n d
does not have any over-representation of hereditary
breast cancer. Our study population represents the het-
erogeneous group of patients for whom CYP2D6 testing
might be used in practice. Our patients include both
pre- and post-menopausal cases; however, there is little
evidence to suggest that women with ER-positive breast
cancer respond differently to tamoxifen according to
menopausal status. The Early Breast Trialists Overview
[2] report a similar effect of tamoxifen in women aged
less than 50 years old as those over 50 years of age.
Conclusions
We conclude that the evidence for variation in the effi-
cacy of tamoxifen treatment by CYP2D6 PM/IM func-
tional status is at best limited. It is therefore premature
to use CYP2D6 testing to guide therapy with tamoxifen.
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Additional file 1: Supplementary tables S1 to S6 and S8.
Supplementary table S1: CYP2D6 inhibitors. A table containing the
generic and trade names of CYP2D6 inhibitor drugs used by patients in
the study. Supplementary table S2: All Functional and TagSNPs
attempted. A table containing all the functional and tagSNPs attempted
including those which failed. Supplementary table S3: Power calculations.
Tabulated summary of power available in this study for each variant.
Supplementary table S4: Genotype and allele frequencies. Tabulated
summary of genotype and allele frequencies for each variant. Also the
number of deaths (all-cause) in tamoxifen-treated patients.
Supplementary table S5: Genotype frequencies and results of unadjusted
and adjusted Cox regression analysis of common (tagSNPs) and
functional polymorphisms and overall survival. Supplementary table S6:
Full unadjusted CYP2D6 survival analysis independent of tamoxifen
status. Tabulated summary of the full unadjusted CYP2D6 survival
analysis independent of tamoxifen status. Supplementary table S8:
Summary of previous studies. Tabulated summary of previous studies
relating to CYP2D6 variants, clinical response and tamoxifen.
Additional file 2: Supplementary figure S1: Sequence alignment. The
figure and supporting legends showing the primers and sequences for
CYP2D6 and its known pseudogenes.
Additional file 3: Supplementary table S7: Adherence to REMARK
criteria. Details of the REMARK criteria and how we have adhered to it.
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